<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503655</url>
  </required_header>
  <id_info>
    <org_study_id>2020/0185/HP</org_study_id>
    <nct_id>NCT04503655</nct_id>
  </id_info>
  <brief_title>Multicenter Study Evaluating the Efficacy of an Intervention Aimed at Reducing the Length of Stay After Transfemoral Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>FAST-TAVI II</acronym>
  <official_title>Etude Multicentrique évaluant l'efficacité d'Une Intervention Visant à réduire la durée de séjour après l'Implantation d'Une bioprothèse Aortique Par Voie transfémorale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the first implantation of a percutaneous aortic bioprosthesis (TAVI) in 2002 (Cribier&#xD;
      et al. Circulation 2002), TAVI occupies an increasing place in the management of aortic&#xD;
      stenosis (AR) . Initially reserved for inoperable patients at high surgical risk, TAVI is&#xD;
      also recommended in patients at intermediate risk, especially when a femoral approach (TF) is&#xD;
      possible (Baumgartner et al. Eur Heart J. 2017).&#xD;
&#xD;
      Currently, there is no recommendation regarding length of stay after TAVI and practices are&#xD;
      extremely heterogeneous. Despite the growing experience of centers, better patient selection&#xD;
      and a reduction in complications, the length of stay after TAVI remains very high in France.&#xD;
&#xD;
      Faced with the great disparity observed between the centers, efforts are necessary to educate&#xD;
      the centers in order to further reduce the length of stay after TF-TAVI. The aim of the study&#xD;
      is to evaluate the effectiveness of an intervention based on training teams to reduce the&#xD;
      length of stay after TF-TAVI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study, there is a randomization of the participating centres in two groups.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effectiveness of a multi-component organizational intervention</measure>
    <time_frame>Year 1</time_frame>
    <description>Proportion of patients benefiting from TF-TAVI with a length of stay less than or equal to 3 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the intervention</measure>
    <time_frame>Day 30</time_frame>
    <description>This outcome will be evaluated using :&#xD;
the average length of stay,&#xD;
the 30-day rehospitalization rate and&#xD;
the 30-day death rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the budgetary impact of the intervention</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome will be assessed using:&#xD;
the hospital costs from the point of view of the hospital and&#xD;
the financial gains for health insurance that would be associated with the generalization of the intervention in France.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the implementation of the intervention</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome will be evaluated using the rate of adherence of the centers to the procedures aiming to reduce the length of stay (questionnaires)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the factors associated with the effectiveness and safety of the intervention</measure>
    <time_frame>Year 1</time_frame>
    <description>This outcome will be assessed using factors associated with lengths of stay less than or equal to 3 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The randomized centres in this group will be follow a training dedicated on implementation of &quot;organizational&quot; and &quot;therapeutic&quot; measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The randomized centres in this group will not change their practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training</intervention_name>
    <description>Training dedicated on implementation of &quot;organizational&quot; and &quot;therapeutic&quot; measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient over 18 years of age;&#xD;
&#xD;
          2. Patient hospitalized for TF-TAVI&#xD;
&#xD;
          3. Patient affiliated or benefiting from a health insurance scheme&#xD;
&#xD;
          4. Patient having read and understood the information letter and having signed the&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of&#xD;
             effective contraception (as defined by the WHO) or postmenopausal woman without&#xD;
             confirmation diagnosis obtained (amenorrhea not medically induced for at least 12&#xD;
             months before the initiation visit) ; 1&#xD;
&#xD;
          2. Person deprived of their liberty by an administrative or judicial decision or person&#xD;
             placed under the protection of justice / guardianship or curatorship&#xD;
&#xD;
          3. History of illness or psychological or sensory abnormality likely to prevent the&#xD;
             subject from fully understanding the conditions required for participating in the&#xD;
             protocol or preventing him from giving his informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Durand, MD</last_name>
    <phone>+33 2 32 88 54 07</phone>
    <email>eric.durand@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Béziau-Gasnier, PhD</last_name>
    <phone>0232886766</phone>
    <email>delphine.beziau-gasnier@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Tribouilloy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Saint Martin</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor (AP-HP)</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Teiger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Lorgis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Darrodes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou (AP-HP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Spaulding</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Gatien</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Lenght-of-stay</keyword>
  <keyword>Medico-economy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

